How to Find the Right Oligonucleotide CDMO

Oligonucleotide manufacturing is a specialized part of the pharmaceutical manufacturing market.

A company may advertise oligonucleotide capabilities broadly, but the actual fit can depend on chemistry, sequence, scale, purification, analytical requirements, and development stage.

That means a good sourcing process should move quickly beyond the label.

The useful question is:

Which oligonucleotide CDMO appears capable of supporting the chemistry and manufacturing needs of this specific program?

An oligonucleotide CDMO provides outsourced development and manufacturing services for oligonucleotide-based products.

Depending on the organization, services may include:

• process development
• synthesis
• purification
• analytical development
• scale-up
• GMP manufacturing
• conjugation
• formulation support
• stability testing
• clinical or commercial supply

Some providers focus primarily on oligonucleotide drug substance.

Others may offer a broader set of development and drug product services.

“Oligonucleotide” is a broad category.

Programs can involve different therapeutic approaches and chemistries.

Before comparing CDMOs, the sponsor should define the molecule and manufacturing requirements as clearly as possible.

That may include:

• sequence characteristics
• chemistry
• modifications
• conjugation requirements
• development stage
• required scale
• purity requirements

These factors can materially change which manufacturers are relevant.

Oligonucleotide synthesis is a core selection criterion.

Sponsors should understand whether the proposed CDMO has experience with the type of chemistry involved in the program.

Potential considerations include:

• synthesis platform
• process-development experience
• scale
• reagent handling
• process robustness
• manufacturing controls

A general statement that a company manufactures oligonucleotides does not automatically mean it is appropriate for every program.

Purification can become a significant part of oligonucleotide manufacturing.

Sponsors should investigate whether the CDMO can support the purity requirements and scale of the program.

Potential considerations may include:

• purification platform
• process-development support
• impurity profile
• yield
• scale
• downstream processing

The manufacturing strategy should balance product quality, process performance, and scalability.

Some oligonucleotide programs involve conjugation to another molecule or delivery component.

If conjugation is required, that becomes an important sourcing criterion.

The sponsor should determine whether the CDMO performs the relevant work internally or whether another manufacturing partner would be involved.

This can affect:

• process coordination
• material transfer
• analytical testing
• timing
• supply-chain complexity

Oligonucleotide programs can require specialized analytical support.

Depending on the product, testing may involve areas such as:

• identity
• purity
• sequence confirmation
• content
• impurities
• residual materials
• stability

The sponsor should understand whether the CDMO has the relevant methods and development expertise in-house.

Analytical capabilities can be particularly important during process development and scale-up.

An early clinical program may require a very different production environment from a late-stage or commercial program.

Sponsors should evaluate:

• development scale
• clinical manufacturing scale
• commercial scale where relevant
• practical batch sizes
• scale-up strategy

The right CDMO should fit the program's current needs without forcing the sponsor into an unnecessarily large or inflexible manufacturing model.

Early oligonucleotide programs may still need significant process-development work.

The sponsor may require support with:

• synthesis optimization
• purification development
• analytical development
• scale-up
• impurity control

A strong manufacturing facility does not automatically mean the organization has the development depth required by an early-stage program.

Sponsors should define how much support they need before selecting a partner.

The relevant manufacturing facility should be identified as early as possible.

Large organizations may operate several sites with different capabilities.

Sponsors should understand:

• where synthesis occurs
• where purification occurs
• where analytical work is performed
• whether multiple sites are involved
• what equipment is available

Facility-level information can help turn a broad company comparison into a more practical manufacturing decision.

As with other modalities, appropriate facility-level regulatory information should be part of preliminary diligence.

FDA Form 483 information, where available and relevant, can help sponsors identify questions for deeper review.

Regulatory history should not be reduced to a simple score.

Formal quality and vendor qualification remains the sponsor's responsibility.

Specialized oligonucleotide manufacturing may involve long lead times for equipment, materials, scheduling, or analytical work.

Sponsors should ask about:

• development start
• manufacturing slots
• raw materials
• synthesis timing
• purification timeline
• analytical lead times
• release timing

Availability can change and should be confirmed directly with the manufacturer.

Pharma Connect Navigator helps sponsors search for manufacturing partners based on structured project requirements.

Sponsors can define modality, development stage, manufacturing capabilities, scale, regulatory requirements, timing, geography, budget, and support needs.

PCN helps identify potentially relevant CDMO companies and facilities and provides a structured way to compare project fit.

Sponsors can investigate available facility information, capabilities, equipment, and regulatory context before deciding which manufacturers appear worth advancing.